Recent advances in tartgeted therapy of renal cell carcinoma

Abstract

Targeted therapy currently represents the standard of care for patients with metastatic renal cell carcinoma (mRCC). Several breakthrough trials were published in 2015, leading to changes in mRCC treatment algorithms, especially the second-line therapy.

These trials confi rmed the effi cacy of three newdrugs: the immune checkpoint inhibitor nivolumab and the kinase inhibitors lenvatinib and cabozantinib

Keywords

• renal cell carcinoma
• targeted therapy
• nivolumab
• lenvatinib
• cabozantinib